25 Nov 2013 10:57
Andrew Derodra Commences Role as Chief Financial Officer
LONDON, ENGLAND, 25 November 2013 - Further to the announcement on 22 August 2013 regarding the appointment of Andrew Derodra as Chief Financial Officer and an Executive Director, Skyepharma PLC (LSE: SKP), the expert oral and inhalation drug delivery company, today confirms Andrew Derodra's appointment to the Company and the Board of Directors with immediate effect.
Mr Derodra, 47, joins Skyepharma from Tate & Lyle, where he had been Group Vice President Finance & Control since 2011. He has spent 25 years working in senior finance roles within five FTSE100 groups including SABMiller, Diageo, British Airways and Reed Elsevier.
-Ends-
For further information please contact:
Skyepharma PLC | |
Peter Grant, Chief Executive Officer | +44 207 881 0524 |
FTI Consulting | |
Julia Phillips/Stephanie Cuthbert/Natalie Garland-Collins | +44 207 831 3113 |
About Skyepharma
Skyepharma combines proven scientific expertise with validated proprietary drug delivery technologies to develop innovative oral and inhalation pharmaceutical products. The Group receives revenues from 14 approved products in the areas of inhalation, oral, topical and injectable drug delivery as well as generating income from the development of further products and technology licenses. The products developed by the Group are marketed throughout the world by big pharmaceutical as well as specialty pharma as well as speciality pharmaceutical companies. For more information, visit www.skyepharma.com.